关于我们
Ambys Medicines is focused on unlocking the full potential of hepatocyte transplantation and transforming the treatment of severe liver disease. Ambys’ proprietary cell therapy platform potentially solves the supply constraints that have hindered progress, catalyzing the field and fundamentally transforming the approach to treating severe liver disease. Our lead program, AMI-918, and future engineered hepatocyte cell therapies are being developed across the spectrum of severe liver disease, including those of acquired and genetic origins.
- 网站
-
https://www.ambys.com
Ambys Medicines的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，California
- 类型
- 私人持股
- 创立
- 2018
地点
-
主要
获取路线
131 Oyster Point Blvd
Suite 200
US，California，South San Francisco，94080
Ambys Medicines员工
-
Maggie Wong
Director, People Operations at Ambys Medicines
-
John McKeon, CPA
VP Finance and Controller at Ambys Medicines, Inc.
-
Abeba Demelash Ph.D.
Senior Scientist I at Merck
-
Rhonda Wiler, DVM, DACLAM
Vice President - In Vivo Technical Ops | Vivarium planning/operations | Attending Veterinarian | Genetically modified animal models